Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VaxPro (also known as M-M-RvaxPro) is a live attenuated trivalent vaccine developed by Merck Sharp & Dohme (MSD) for the active immunization against measles, mumps, and rubella. It contains the Enders' attenuated Edmonston strain of measles virus, the Jeryl Lynn (Level B) strain of mumps virus, and the Wistar RA 27/3 strain of rubella virus. The vaccine is indicated for individuals 12 months of age or older and works by stimulating the immune system to produce protective antibodies and cellular responses against these three viral pathogens. It is the European brand name for the vaccine marketed as M-M-R II in the United States.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on measles, mumps, and rubella vaccine (live).